Indivior Share Discussion Threads

[newtoaim] 24/7/2020 15:38

Dnt gt spiked

[steeplejack] 24/7/2020 15:37

The shining bloody beacon and they won't make a price online!

[gregmorg] 24/7/2020 15:35

Ah, some light at the end of the tunnel! ! !

[the stigologist] 22/7/2020 23:05

Does seem about bloody time they released Information relevant to Investors

GLOBAL MEDIA CONTACTS
Email: [e-mail]
Phone: [phone]

UK Media Contacts

Tulchan Communications LLP
85 Fleet Street
London
EC4Y 1AE
[e-mail]
Phone: [phone]


Been two weeks since they started recruiting

[waldron] 22/7/2020 19:01

Upcoming Events

The information provided below is provisional and subject to change. Details of each event, including venue information, will be confirmed shortly before they are due to take place.

First Half and Second Quarter 2020 Financial Results on July 30th


8 DAYS AND COUNTING

[florenceorbis] 22/7/2020 08:04

Citigroup Neutral UP from 45.00 to 85.00 Reiterates

[t0pgrader] 21/7/2020 11:26

Any explanation as to why company hasn't announced commencement of phase 1 trial of C4X_3256 ?

[jimboau] 18/7/2020 03:41

The really smart money has been accumulating, going to be some run up to the results.

[waldron] 17/7/2020 19:33

Scopia Capital Management LP

Scopia Management, Inc.

HOLDINGS UP

[la forge] 16/7/2020 13:12

RNS Number : 2368T

Indivior PLC

16 July 2020

Indivior to Announce First Half and Second Quarter 2020 Results on July 30th and Host Conference Call Presentation

Slough, UK, and Richmond, VA, 16 July 2020 - Indivior PLC (LON: INDV) today announced that it will release its first half and second quarter 2020 results on July 30(th) at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com .

Key members of Indivior's leadership team led by Mark Crossley, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 p.m. London time (7:00 a.m. U.S. Eastern).

Access the Live Webcast / Call for the Results on July 30(th)

The live webcast event will be available on the "Investors" section of the company's website at www.indivior.com . The webcast link is hxxps://edge.media-server.com/mmc/p/ot3s33ij . Participants also may access the results presentation telephonically: US participants 1-631-510-7495; international participants [phone]. Please reference confirmation number 6735858. A replay of the presentation will be available at www.indivior.com .

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: [phone] or [e-mail]

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NOREAEXKFEXEEFA

(END) Dow Jones Newswires

July 16, 2020 08:00 ET (12:00 GMT)

[waldron] 15/7/2020 17:54

Price (GBX)
78.40 -4.22%

Open / Last close
80.90 / 78.40

High / Low
83.40 / 78.20

Bid / Offer
78.20 / 78.80

[waldron] 15/7/2020 17:50

[United States] INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 07/15 00:18:26 pm

9.6 USD -1.03%

[waldron] 15/7/2020 14:16

Price (GBX)
80.20 -2.02%

Open / Last close
80.90 / 81.85

High / Low
83.40 / 79.45

Bid / Offer
80.15 / 80.50

[waldron] 14/7/2020 18:26

INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 07/14 01:09:05 pm

9.66 USD -4.92%

[waldron] 14/7/2020 15:56

Support 78.25p


INDIVIOR (INDV)

Real-time Estimate Quote. Real-time Estimate CHI-X - 07/14 03:54:06 pm

81.6 GBX -3.32%

[waldron] 14/7/2020 15:53

[United States] INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 07/14 03:36:21 pm

9.53 USD -6.20%

STILL DUMPING

[waldron] 13/7/2020 17:55

Dow surges 450 points amid coronavirus vaccine optimism, Pfizer jumps 5%

Published Sun, Jul 12 20206:04 PM EDT

Updated 6 Min Ago

Fred Imbert
@foimbert

Yun Li
@YunLi626




[United States] INDIVIOR PLC (INVVY)

Delayed Quote. Delayed OTC Bulletin Board - Other OTC - 07/13 05:34:16 pm

10.28 USD -1.15%

Dumping continues

[kazoom] 12/7/2020 19:32

Re the twinpetes podcast, for anyone wanting to here conkers' and wheelie's views but daunted by the 1 hour 20 minute duration; the INDV starts just after 49 minutes in.

To be frank it's not awfully insightful, but I often find it useful to understand what they are thinking.

[the stigologist] 12/7/2020 17:18

If they were any good at investing they'd be working for hedge funds not writing for the FT

[grupo guitarlumber] 08/7/2020 20:41

Dumping galore in the usa otc market

[ih_116147] 08/7/2020 09:35

DNL =BIG Drug with potential FDA approval in 2 months = 5+ BAGGER GEM

Diurnal Group (DNL) = MCap £38 M / Cash £15 M or enough untill early 2022 / LOTS of BIG milestones on the way = Still the MOST attractive and CHEAPEST pharma stock in UK has potential to run toward 200p very fast especially on approval of Alkindi in USA (expected in September) and Chronocort in Europe (expected in Q1 ) =STRONG BUY AGGRESSIVE a sleeping iant here .GL

Market Cap £38 million
Cash £15 million
Price 30p


Alkindi approval in Australia expected this Quarter
Alkindi approval in Israel expected this Quarter
FDA decision for Alkindi on September 29
EMA Decision for Chronocort expected in early Q1 2021

[the stigologist] 08/7/2020 09:29

INDV2000 Clinical Trial is now recruiting

Potentially huge news for C4XD

£16m Mkt Cap they could be due significant milestone on this $294m licence deal

[la forge] 08/7/2020 08:39

Aggregate of Standard Life Aberdeen plc affiliated


Selling a few on behalf of clients




Total number of voting rights of issuervii
732,436,173





13.42% still held